Dengue is a viral infectious disease that affects not only humans but also mosquitoes that affect animals, caused by dengue viruses in flaviviruses and flaviviruses. Dengue fever usually spreads from one person to another through the bite of an infected aedes aegypti mosquito. Symptoms of this disease include high fever, fatigue, headache, diarrhea, muscle aches, skin rash, anemia, and vomiting. Severe dengue can cause seizures, yellow skin, coma, or death. Dengue fever causes CNS symptoms such as abnormal neurological signs, degree of consciousness impairment, concentration and general convulsion, delirium. The cause of neurological symptoms in dengue fever is high fever. Many tests are available to confirm the diagnosis, including detecting antibodies to virus or RNA in the market. Dengue management is a challenge. There are other causes underlying dengue fever clinical events that require multimodal and effective treatment approaches.
Report Overview @ https://www.transparencymarketresearch.com/dengue-virus-diagnostic-tests-market.html
The global Dengue virus diagnostic testing market is expected to grow significantly due to the increased incidence of dengue fever. According to the World Health Organization, the number of people suffering from dengue fever has increased from 2.2 million in 2010 to 3.2 million in 2015. Actual figures are insignificant. According to data released by Bhatt et al., There are about 390 million dengue cases worldwide each year, and the number continues to increase. In the Americas, only 2.3 million dengue cases were found, of which 10,200 were diagnosed with serious dengue fever, resulting in 1,181 deaths in 2015. Dengue fever is a viral disease affecting people throughout Europe, South America and Asia. In 2015, there were more than 111,000 cases of dengue fever reported worldwide and more than 169,000 cases in the Philippines. This represents an impressive growth of 16% and 59.5% respectively compared to 2014. However, markets with low awareness and high diagnostic rates for emerging countries are currently limiting the market. As the awareness of the symptoms of dengue fever increases and government efforts to provide healthcare facilities increase, we expect the market to have ample opportunities.
Request a brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43634
The global market for dengue virus diagnostic tests can be categorized by type, end user, and region. Depending on the type of virus, the market for virus diagnostic tests can be classified as biomarker assay, rapid molecular assay, and IsoAmp assay. The Tennessee virus diagnostic testing market can be divided into hospitals and research institutes from the end user perspective. By region, it can be divided into Northern Europe, Europe, Central and South America, Asia-Pacific and the Middle East and Africa. Each region is subdivided into specific countries, such as the US, Canada, Germany, UK, Brazil, China, India, Japan, and GCC countries. North America dominated the global dengue virus diagnostic testing market in 2017. Asia Pacific and Latin America are emerging markets. The region's market is expected to expand rapidly during the forecast period from 2018 to 2026. The strong growth in the region is attributable to increased incidence of dengue fever, expansion of the medical industry, and increased government investment in healthcare development Infrastructure.
The major players working in the global dengue virus diagnostic testing market are Arkray Inc., Ceres Nanosciences Inc., F. Hoffmann-La Roche Ltd, FK-Biotecnologia SA, Corgenix Medical Corp., QuantuMDx Group Ltd., Quidel Corp, Sansure Biotech Inc. , Whidiag SAS, Pictor Ltd. And other celebrities. Key players are actively involved in a variety of expansion strategies to gain competitive advantage in the industry. Collaboration, partnerships, contracts, and new product launches are some of the key strategies that market players apply.